Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer

Enrollment Criteria:

* Female patients with histologically confirmed early-stage breast cancer at the age of ≥18 and ≤75 , who have received radical surgical treatment of breast cancer (including modified radical mastectomy and breast-conserving surgery) while have not received neoadjuvant chemotherapy. EC\*4-T\*4 chemotherapy (T is paclitaxel or docetaxel) protocol is expected, and there is no herceptin indication or the patients are voluntarily not to be treated with herceptin.
* Patients with KPS（Karnofsky Performance Status) scores ≥ 80;
* Patients with ECOG score ≤ 1;
* Expected survival ≥ 3 months;
* The functional level of main organs must meet the following requirements (no blood transfusion, no leucocyte or platelet-ascending drugs used within 2 weeks before screening):1)Blood Routine: Neutrophil (ANC) ≥ 1.5 x 109/L;Platelets (PLT) ≥ 90 x 109/L; Hemoglobin (Hb) ≥ 90 g/L;2) Blood Biochemistry Total bilirubin (TBIL) ≤ 1.5 x ULN;L-Alanine (ALT) and aspartic transaminase (AST) ≤ 2 x ULN;Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 x ULN;
* Cooperate to complete questionnaire accurately recording occurrence and severity of neurotoxicity
* Sign the informed consent form.

Exclusion Criteria:

* There are any toxicity events of peripheral nervous system before enrollment, including: FACT-Ntx subscale score \< 44;≥ Grade 1 peripheral toxicity according to CTCAE Version 4.0 rating scale;≥ Grade 1 peripheral toxicity according to ENS rating scale;All other pathological symptoms or diseases might affect the evaluation of adverse neurotoxic effects
* Patients having received other drug treatments might cause similar adverse neurotoxic effects within 4 weeks prior to the treatment of this protocol, or receive concurrent neurotoxic drugs. Including: Taxanes or analogues; Vinca alkaloids or analogues; Platinums or analogues; Cytarabine, thalidomide, bortezomib, or procarbazine; Other drugs or treatments might cause peripheral neurotoxicity
* Patients in poor general conditions, with KPS (Karnofsky performance status) scores \< 80;
* Pregnant or lactating women；
* Patients (female) having the possibility of fertility but unwilling or not taking effective contraceptive measures
* Patients also having other neurological abnormalities who cannot accurately record the occurrence and severity of neurotoxicity;
* Patients known allergy to trial drugs or excipient compositions of these products;
* Patients with inherited glucose and lipid metabolism abnormalities (gangliosidosis such as amaurotic family idiocy and retinopathy);
* Patients not suitable for treatment of ganglioside;
* Active infection (depending on the judgment of investigators);
* Patients with serious concurrent diseases might harmful to safety and interfere the scheduled treatment or concomitant diseases might affect the completion of the study, depending on the judgment of investigators.
* Patients with a history of definite neurological or dysphrenia, including epilepsy or dementia.